Disease Patients on Maintenance Haemodialysis in Aden, Yemen: A - - PowerPoint PPT Presentation

Presenter: Assistant Professor Khadiga Aman

Aden University, Faculty of Medicine and Health Sciences, Internal Medicine Department, Khormaksar, Aden, Yemen Email: Khak-2010@hotmail.com Co-authors:

Saba Kassim PhD/ Queen Mary university of London, UK Reema Aman MD/Tayba Haemodialysis centre, Aden, Yemen Aamenah Hawash BSc/ Queen Mary university of London, UK Mustafa Al-Shagga MD/University of Nottingham, Malaysia Sami Al-Dubai PhD/International Medical University / Malaysia

Hepatitis C Virus Infection among End Stage Renal Disease Patients on Maintenance Haemodialysis in Aden, Yemen: A Retrospective Study

• Hepatitis C virus infection (HCV) is a common

nosocomial infection among end stage renal disease (ESRD) patients on haemodialysis (HD)1

• Hepatitis C contributes to high mortality and

morbidity among this patients2

• The prevalence of contracting HCV during

haemodialysis varies from country to country21,18,22

Background

• Tight infection control measures in developed countries

has minimised the transmission rate in this patients3

• HCV still remains high in the developing world4,5,6,7
• Risk factors for HCV transmission in this patients include:
• 1. Transfusion of blood 9,10;
• 2. Sharing HD machines14;
• 3. Performing haemodialysis in multiple centres16,17;
• 4. Duration of haemodialysis16,17; and
• 5. Socio-demographic factors 13,18

Continued……

Aims

To assess the prevalence and factors associated with HCV infection among ESRD patients on HD in the three available centres in Aden, Yemen.

Methods

• A retrospective study was conducted between

May and July 2013 in all the HD centres in Aden city

• Records of 243 patients were reviewed and data
• f 219 patients was extracted and analysed
• Exclusion criteria: aged under 18 years, positive

for HBs Ag and with dual HCV and HBV infection.

• Clinical and non clinical data extracted included:
• a. Anti-hepatitis C positive or negative
• a. Risk factors for HCV transmission

(e.g. Duration of haemodialysis, Surgical intervention and

Attending more than one of haemodialysis centre)

• c. Socio-demographical data

(e.g. age, gender, occupation and marital state)

• Descriptive, bivariate (chi Squared and unpaired T-

Test) and multivariate poisson regression modelling were used in data analyses

Results

88(40.2%) Anti HCV+ 131(59.8%) Anti HCV - 0 0

The mean ±SD age of patients was 47.08±13.9 (range18-80) years, 70% males and 17% were unemployed Of 219 patients 40.2% (95 % CI 33.64 %-46.73%) were anti HCV positive

Table 1: Chi square tests of factors associated with anti HCV-positive (n=219)

variable Anti HCV positive N (%) Anti HCV negative N (%) P-Value

Surgery Yes No 20 (40.8) 68 (40) 29 (59.2) 102 (60) NS Blood transfusion Yes No 67(41.9) 21 (36.2) 93 (58.1) 38 (63.8) NS Access Fistula Catheter 87(42.4) 1 (7.1) 118 (57.6) 13 (92.9) NS Attending HD in more than one centre Yes No 42 (53.2) 46 (32.9) 37(46.8) 94 (67.1) 0.003 Travel Yes No 23 (43.4) 65 (39.3) 30 (56.6) 101(60.8) NS

In bivariate analysis only duration of HD and attending more than one centre for HD associated significantly (p≤ 0.05) with HCV.

a AOR: Adjusted odd ratio; b95%CI: 95% confidence interval

Explanatory variables AORa, 95%CIb P-Value Age 1.01 (99-1.03) .119 Duration of HD 1.01 (1.00-1.02) .0005 Attending more than one centre 1.87 (1.22-2.88) .0004

Table 2: Multivariate analysis of factors associated with anti HCV-positive

In multivariate analysis (Table 2), after controlling for age, the significant predictors of anti-HCV positive were the duration of HD and attending more than one center for HD, (p=0.0005 and p=0.004, respectively).

Discussion

The first retrospective study to report the estimated prevalence of HCV and its associated factors in ESRD patients receiving HD in multiple centres in Aden

A prevalence of 40.2% of HCV infection was found and was

in accord with figures reported in neighbouring countries such as Egypt (42.2%)21, Libya (31.1%)18, Syria (48.9)22

The association of duration of HD with HCV lent further

support to the current literature 23, 17, 4, 24 and likewise the history of receiving HD at more than one HD centre29

Conclusions The prevalence of HCV was significant among ESRD

patients underwent HD in these centres Attending more than one centre for HD, and HD for longer durations predicting contract of HCV among ESRD patients Enhancing existing infection control measures and allocating more resources to HD centres warrants prioritisation and consideration

References

• 1. Iwasa Y, Otsubo S, Sugi O, Sato K, Asamiya Y, Eguchi A, et al. Patterns in the prevalence of hepatitis C virus infection at the

start of hemodialysis in Japan. Clin Exp Nephrol 2008;12(1):53-7. 2. Ingsathit A, Kamanamool N, Thakkinstian A, Sumethkul

• V. Survival advantage of kidney transplantation over dialysis in patients with hepatitis C: a systematic review and meta-
• analysis. Transplantation 2013;95(7):943-8. 3. Espinosa M, Martn-Malo A, Ojeda R, Santamara R, Soriano S, Aguera M, et al.

Marked reduction in the prevalence of hepatitis C virus infection in hemodialysis patients: causes and consequences. Am J Kidney Dis 2004;43(4):685-9. 4. de Jesus Rodrigues de Freitas M, Fecury AA, de Almeida MK, Freitas AS, de Souza Guimaraes V, da Silva AM, et al. Prevalence of hepatitis C virus infection and genotypes in patient with chronic kidney disease undergoing hemodialysis. J Med Virol 2013;85(10):1741-5. 5. Paniagua R, Villasis-Keever A, Prado-Uribe Mdel C, Ventura-Garcia MD, Alcantara-Ortega G, Ponce de Leon SR, et al. Elevated prevalence of hepatitis B in Mexican hemodialysis

• patients. A multicentric survey. Arch Med Res 010;41(4):251-4. 6. Diouf ML, Diouf B, Niang A, Ka EH, Pouye A, Seck A, et al.

[Prevalence of hepatitis B and C viruses in a chronic hemodialysis center in Dakar]. Dakar Med 2000;45(1):1-4. 7. Khattab

• OS. Prevalence and risk factors for hepatitis C virus infection in hemodialysis patients in an Iraqi renal transplant center.

Saudi J Kidney Dis Transpl 2008;19(1):110-5. 8. Jenkins K. A review of the updated European Best Practice Guidelines for the Management of Anaemia in Patients with Chronic Renal Failure. EDTNA ERCA J 2005;31(3):156-9. 9. Ejiofor OS, Ibe BC, Emodi IJ, Ikefuna AN, Ilechukwu GC, Emechebe G, et al. The role of blood transfusion on the prevalence of hepatitis C virus antibodies in children with sickle cell anaemia in Enugu, South East Nigeria. Niger J Clin Pract 2009;12(4):355-8. 10. Northcott MJ, Ong WL, Walsh M, McCarthy P, Belleli D, Tran H, et al. Prevalence of transfusion-acquired hepatitis C in an Australian bleeding disorders population. 13. Bin Selm SA. The seroprevalence of anti-HCV in high-risk dialysis patients. Saudi J Kidney Dis Transpl 2011;22(4):806-7. 14. Barril G, Traver JA. Decrease in the hepatitis C virus (HCV) prevalence in hemodialysis patients in Spain: effect of time, initiating HCV prevalence studies and adoption of isolation measures. Antiviral Res 2003;60(2):129-34. 16. Resic H, Sahovic V, Mesic E, Leto E. [Prevalence and incidence of hepatitis C seroconversion in patients on hemodialysis]. Acta Med Croatica 2003;57(1):39-42. 17. Rinonce HT, Yano Y, Utsumi T, Heriyanto DS, Anggorowati N, Widasari DI, et al. Hepatitis B and C virus infection among hemodialysis patients in Yogyakarta, Indonesia: Prevalence and molecular evidence for nosocomial transmission. J Med Virol 2013;85(8):1348-61.18. Alashek WA, McIntyre CW, Taal MW. Hepatitis B and C infection in haemodialysis patients in Libya: prevalence, incidence and risk factors. BMC Infect Dis 2012;12:265.21. Khodir SA, Alghateb M, Okasha KM, Shalaby Sel S. Prevalence of HCV infections among hemodialysis patients in Al Gharbiyah Governorate, Egypt. Arab J Nephrol Transplant 2012;5(3):145-7. 22. Othman B, Monem F. Prevalence of antibodies to hepatitis C virus among hemodialysis patients in Damascus, Syria. Infection 2001;29(5):262-5. 23. Amiri ZM, Shakib AJ, Toorchi M. Seroprevalence of hepatitis C and risk factors in haemodialysis patients in Guilan, Islamic Republic of Iran. East Mediterr Health J 2005;11(3):372-6. 24. Gasim GI, Hamdan HZ, Hamdan SZ, Adam I. Epidemiology of hepatitis B and hepatitis C virus infections among hemodialysis patients in Khartoum, Sudan. J Med Virol 2012;84(1):52-5. 29. Su Y, Yan R, Duan Z, Norris JL, Wang L, Jiang Y, et al. Prevalence and risk factors of hepatitis C and B virus infections in hemodialysis patients and their spouses: a multicenter study in Beijing, China. J Med Virol 2013;85(3):425-32.